24 Treatment of Staphylococcus aureus biofilm-related infections represents an important 25 medical challenge worldwide, as biofilms, even of drug-susceptible S. aureus strains, are 26 highly refectory to conventional antibiotic therapy. Nitroxides were recently shown to induce 27 dispersal of Gram-negative biofilms in vitro, but their action against Gram-positive bacterial 28 biofilms remains unknown. Here we demonstrate that the biofilm dispersal activity of 29 nitroxides extends to S. aureus, a clinically important Gram-positive pathogen. Co-30 administration of the nitroxide CTEMPO with ciprofloxacin significantly improved the 31 antibiotic's biofilm-eradication activity against S. aureus. Moreover, covalently linking the 32 nitroxide to the antibiotic moiety further reduced ciprofloxacin's minimal biofilm eradication 33 concentration. Microscopy analysis revealed that fluorescent nitroxide-antibiotic hybrids 34 could penetrate S. aureus biofilms and enter into cells localising at the surface and base of 35 the biofilm structure. No toxicity was observed for the nitroxide CTEMPO and the nitroxide-36 antibiotic hybrids against human cells. Taken together, our results show that nitroxides can 37 mediate dispersal of Gram-positive biofilms and that dual-acting biofilm-eradication 38 antibiotics could provide broad-spectrum therapies for the treatment of biofilm-related 39 infections.
INTRODUCTION 41
Staphylococcus aureus is a Gram-positive commensal and opportunistic human pathogen, 42 which is a major cause of nosocomial and community-acquired infections (1). The inherent 43 ability of S. aureus to attach to medical devices and host tissues and establish biofilms is a 44 major driver of failing antibiotic therapies and the persistence of chronic infections (2-4).
Thus, there is an urgent need for novel strategies for the treatment and eradication of S. 46 aureus biofilms. 47 Current antimicrobial strategies, which are effective against planktonic bacteria, often 48 have little or no effect when administered to biofilms (5, 6) . During infection, bacteria reside 49 mostly within biofilms but can revert to the planktonic lifestyle by modulating the expression 50 of specific genes (7) . Consequently, the development of small molecules with the ability to 51 trigger a cell change from biofilm to the planktonic state has become a promising area of anti-52 biofilm research (8, 9) . 53 One of the most promising small molecules with anti-biofilm activity is nitric oxide 54 (NO), which has been shown to inhibit biofilm formation and trigger biofilm dispersal (10-12) 55 in a variety of biofilm-forming bacteria (13). In Pseudomonas aeruginosa, for example, 56 treating a mature biofilm with sub-lethal NO concentrations (pM to nM range) triggers a 57 transition from the sessile (biofilm) to the motile (planktonic) state, providing a means of 58 effective antibiotic therapy (11, 13) . The anti-biofilm properties of NO in P. aeruginosa are 59 mediated by regulation of intracellular levels of the secondary messenger cyclic dimeric 60 guanosine monophosphate (cyclic di-GMP), which plays a pivotal role in biofilm development; 61 high levels facilitate biofilm formation, while low levels prompt biofilm dispersal (7, 14) . 62 However, the targeted and controlled delivery of NO to biological systems as therapies is a 63 challenge due to the reactive nature and short half-life (0.1 -5 seconds) (15) of the gaseous 64 molecule. Consequently, methods for circumventing this challenge have been the focus of 65 intensive research over the past several years, with the use of NO-donors in biofilm dispersal 66 now comprehensively documented (16, 17) . A variety of NO-donor compounds with anti-67 biofilm activity have already been described. However, donor molecules are often themselves 68 inherently unstable (18), necessitating an alternative approach. 69 Nitroxides are long-lived, stable free radical species, which contain a disubstituted 70 nitrogen atom linked to a univalent oxygen atom (19) . Nitroxides are considered sterically 71 hindered, structural mimics of NO, as both compounds contain an unpaired electron, which 72 is delocalized over the nitrogen-oxygen bond. The biological activity of nitroxides is often 73 attributed to their NO-mimetic properties, with both being efficient scavengers of protein-74 derived radicals (20) . Nitroxides, however, are mostly air-stable crystalline solids, in contrast 75 to NO, which is unstable and gaseous at room temperature. This significant difference makes 76 nitroxides ideal candidates for circumventing the handling and delivery issues associated with 77 NO. 78 We have previously demonstrated the ability of nitroxides to inhibit and disperse 79 bacterial biofilms of P. aeruginosa and E. coli (21, 22) . Nitroxides were also shown to enhance 80 biofilm antibiotic susceptibility when co-administered as a combined treatment (23). 81 Furthermore, we have shown that by covalently tethering a nitroxide to the antibiotic 82 ciprofloxacin and thus delivering the antibiotic at the site of nitroxide mediated dispersal, we 83 could achieve effective eradication of mature P. aeruginosa biofilms (24, 25) . While the 84 dispersal and anti-biofilm properties of nitroxides have been successfully documented against 85 Gram-negative bacteria, their anti-biofilm properties against Gram-positive bacteria remain 86 unexplored. Here we have employed a reproducible, high-throughput in vitro biofilm assay to 87 comprehensively examine the full antimicrobial, anti-biofilm, and biofilm-eradication 88 potential of nitroxides and antibiotic-nitroxide hybrids against S. aureus. Our findings 89 demonstrate the anti-biofilm action of nitroxides against a clinically important Gram-positive 90 pathogen extending this promising therapeutic strategy to a large number of S. aureus 91 biofilm-related infections.
92

RESULTS
93
The nitroxide CTEMPO can disperse established S. aureus biofilms. 94 To examine the biofilm dispersal properties of the nitroxide 4-carboxy-2,2,6,6-95 tetramethylpiperidin-1-yloxyl (CTEMPO) against S. aureus in a high-throughput system, we 96 modified the static Calgary Biofilm Device (CBD) in a way that allows the specific eradication 97 of disperser cells with antibiotics (ciprofloxacin). This methodology ensured that S. aureus 98 cells were immediately eliminated after dispersing from the biofilm (ciprofloxacin 99 susceptible) preventing them from reverting to biofilm growth (ciprofloxacin resistant). This 100 modification allowed us to monitor biofilm dispersal in a static biofilm system similar to that 101 achieved in a dynamic flow cell system, where media influx physically removes disperser cells. 102 In our system, this was achieved by the addition of 6 µM ciprofloxacin (minimum bactericidal 103 concentration (MBC) against disperser S. aureus ATCC 29213 cells) in every well treated with 104 the nitroxide CTEMPO at a concentration range. 105 Using this methodology, established S. aureus ATCC 29213 biofilms were co-treated 106 with CTEMPO (160 -2.5 µM) and ciprofloxacin (6 µM) or ciprofloxacin alone (6 µM) for 24 107 hours. Viable bacteria remaining in the treated biofilms were recovered in media without 108 nitroxide or antibiotics and monitored for growth, with lag time recorded as a direct measure 109 of the initial colony forming units (CFU) present in each well. Significant increase in lag time, 110 indicative of a significant reduction in biofilm-associated bacteria recovered post-treatment, 111 was observed at CTEMPO concentrations in the range of 10 to 80 µM (p= 0.0003, Kruskal-112 6 antimicrobial activity was observed for CTEMPO alone at those concentrations against 114 planktonic or biofilm-residing S. aureus ATCC 29213 cells (MIC >3200 µM, MBEC >1200 µM; 115 Table 1), the nitroxide was most likely inducing cell dispersal in biofilms, not bacterial killing. 116 CTEMPO alone (no ciprofloxacin) had no impact on the number of viable bacteria recovered 117 from the biofilm.
118
CTEMPO co-administration improves the efficacy of ciprofloxacin against S. aureus biofilms. 119 As nitroxides appear to induce S. aureus biofilm dispersal, we sought to examine whether this 120 could improve the efficacy of ciprofloxacin against established S. aureus biofilms. 121 Ciprofloxacin is a commonly prescribed fluoroquinolone antibiotic with potent antimicrobial 122 activity against planktonic S. aureus ATCC 29213 (26). We confirmed the MIC of ciprofloxacin 123 for this strain to be within the previously published range (1.5 -0.4 µM; Ciprofloxacin-nitroxide hybrids are potent S. aureus biofilm-eradication agents. 139 Considering the synergistic effect of nitroxide-ciprofloxacin co-administration on S. aureus 140 biofilm eradication, we evaluated whether combining the nitroxide and antibiotic within one 141 molecule would offer greater improvement. We rationalized that by localising the antibiotic 142 directly at the site of nitroxide-mediated dispersal, it could more effectively eradicate 143 dispersed cells than in combination treatment. To test this hypothesis, we utilized several 144 ciprofloxacin-nitroxide hybrids that we have previously generated ( Figure (Table 1) . However, cipro-155 TMIO was by far the most potent agent with an MBEC value of ≤64 µM. This made cipro-TMIO 156 at least 4-fold more potent than ciprofloxacin/CTEMPO co-treatment (MBEC ≤256 µM) and 157 >64-fold more potent than ciprofloxacin alone (MBEC ≤4096 µM) against S. aureus biofilms. 158 These results demonstrate the advantage of covalently linking a nitroxide moiety to an 159 antibiotic to enhance its activity against Gram-positive biofilms. probe for studying S. aureus biofilm eradication by nitroxide-antibiotic hybrids. We first 167 established the MBEC value for fluoro-TEMPO (MBEC ≤720 µM; Table 2 ) and found it to be at 168 least 5-times more potent than ciprofloxacin treatment of S. aureus ATCC 29213 biofilms, 169 further supporting the increased potency of tethered nitroxide-antibiotic hybrids. 170 Importantly we showed that this effect was specific to the presence of the free radical 171 nitroxide as the methoxyamine derivative fluoro-TEMPOMe had lost its antibacterial activity 172 (MIC >1200 µM and MBEC >1480 µM; Table 2 ). 173 We then treated established S. aureus biofilms with sub-MBEC concentrations of TEMPOMe did appear to enter biofilm-residing cells, instead, it appeared to be localized 183 within the EPS of the biofilm (Figure 4) . These results suggest that the nitroxide free radical 184 may facilitate EPS penetration and cell entry. (14, 29, 30) . The signalling nucleotide cyclic di-GMP has been shown to play a pivotal role in 214 biofilm formation and control, with higher levels facilitating biofilm formation and lower 215 levels triggering biofilm dispersal (31-33). Interestingly, our finding that the optimal nitroxide 216 concentration for biofilm dispersal is similar between Gram-positive and Gram-negative 217 species may suggest that the mechanism by which nitroxide-mediated dispersal occurs is 218 similar between these species. 219 Our study demonstrates that the nitroxide CTEMPO potentiates the activity of 220 ciprofloxacin against S. aureus biofilms, significantly improving its eradication efficacy (>16-221 fold MBEC improvement). This is consistent with our previous results using further supporting a similarity between the mechanism of NO-and nitroxide-mediated 227 biofilm dispersal. Importantly, the ability of nitroxides to enhance the biofilm-eradication 228 activity of antimicrobials against biofilms is also comparable to other leading methods such 229 as the use of D-amino acids (8-fold improvement over antibiotic alone) (34) and Cis-2-230 decenoic acid (>4-fold improvement over antibiotic alone) (35). Taken together these results 231 support the use of nitroxides as effective enhancers of antibiotic biofilm-eradication activity. 232 As an improvement to co-treatment, a currently emerging alternative has been the 233 development of dual-acting hybrid compounds. Such compounds combine the anti-biofilm 234 activity of a dispersal agent with an antimicrobial agent to produce a hybrid compound which 235 can both disperse and eradicate biofilm-residing cells. We have previously utilized this 236 strategy to produce ciprofloxacin-nitroxide hybrids which exhibited potent P. aeruginosa and 237 E. coli biofilm-eradication activity (24, 25, 36) . In this study, we have shown that some of these 238 ciprofloxacin-nitroxide hybrids are also potent S. aureus biofilm-eradication agents. 239 Importantly, cipro-TMIO was able to completely eradicate (99.9%) established S. aureus 240 biofilms at a concentration of only 64 µM (MBEC ≤ 64 µM), which is very similar to its P. Hence, the results presented here support the hypothesis that much like co-treatment 271 (nitroxide/antibiotic), the biofilm-eradication activity of nitroxide-antibiotics, such as cipro-272 TMIO and fluoro-TEMPO, also occurs via a dual-action mechanism, were the nitroxide moiety 273 triggers biofilm dispersal, and the antibiotic moiety subsequently eradicates the dispersed 274 cells. This dispersal and eradication cycle may initially occur at the surface of the biofilm 275 ultimately exposing previously protected biofilm-residing cells to the antibiotic and allow the 276 process to be repeated until the biofilm is completely eradicated (Figure 5) . 277 In conclusion, we have demonstrated that the biofilm dispersal activity of nitroxides 278 is not limited to Gram-negative pathogens but also extends to important Gram-positive 279 pathogens. This work also highlights the ability of nitroxides to restore the antibacterial 280 activity of ciprofloxacin against S. aureus biofilms, either by administering them as a 281 combinational treatment or, more potently, as nitroxide functionalized ciprofloxacin 282 derivatives. While our work has focused on the fluoroquinolone class of antibiotics, the 283 methodology followed is easily adaptable to other antimicrobial classes, widely expanding the 284 possible repertoire of anti-biofilm agents that are so urgently needed. Furthermore, our study 285 has provided a promising new therapeutic strategy that could potentially lead to effective 286 broad-spectrum treatments for biofilm-related infections in the not so distant future.
287
MATERIALS AND METHODS
288
Bacterial strains and culture media. (39). 333 Briefly, overnight LB bacterial cultures were diluted to 10 6 CFU mL -1 in LB and used to 334 inoculate the enclosed flat bottom 96-well plate with ∼10 5 bacterial cells (130 µL) in each 335 well. The peg lid was inserted into the inoculated wells, and the complete CBD was incubated 336 in a shaking incubator at 150 rpm, 37 ˚C, and 95% relative humidity for 24 hours. 
